| Saigene Corporation | |||
| Proposed Ticker: | SGEN | 1725 220th Street SE | |
| Exchange: | NASDAQ-Small Cap Market | Bothell, WA 98021 | |
| Industry: | Service (SIC Code 8731) | (206) 485-5377 | |
| Type of Shares: | Common Shares | Filing Date: | 2/13/97 | |
| U.S. Shares Filed: | 1,000,000 | Filing Price: | $6.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $6,000,000 | |
| Primary Shares: | 1,000,000 | Expenses: | $400,000 | |
| Secondary Shares: | 0 | Shares Out After: | 2,050,000 |
| Manager | Tier | Phone |
| Dickinson & Co. | Lead Manager | (515) 247-8191 |
| Issuer's Law Firm: | Wilson, Sonsini, Goodrich & Rosati |
| Bank's Law Firm: | O'Connor, Cavanagh, Anderson, Westover |
| Auditor: | KPMG Peat Marwick |
| Registrar/Transfer Agent: | American Stock Transfer & Trust Co |
Dollar amounts in U.S. millions except for per share data | |||||
| 3 Month Ending Financials | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 9/30/96 | 12/31/96 | 12/31/96 | |||
| Revenue: | $0.00 | $0.05 | Assets: | $1.40 | |
| Net Income: | -$0.05 | -$0.21 | Curr Assets: | ||
| EPS: | -$0.04 | -$0.15 | Liabilities: | $1.65 | |
| Prior EPS: | Curr Liabilities: | ||||
| Cash Flow/Oper: | -$0.23 | Equity: | -$0.25 | ||
| Cash Flow/Fin: | Cash: | ||||
| Cash Flow/Inv: | |||||
| Business Description |
| The company is a biotechnology company focused on the development of portable, cost-efficient, rapid and easy to use molecular-based diagnostic tests for a variety of medical and non-medical conditions. The company believes that the successful commercialization of its technology will create numerous point-of-care, on-site, and in the field opportunities to provide diagnostic information, often in less than an hour, at lower costs than currently available alternatives. The company is currently developing a number of product applications, including a sex-typing test for rare birds, a test for the detection of toxic species of harmful sea algae and a genetic probe test for detecting mutations that are specific to AZT drug-resistance in the treatment of human immune deficiency virus, the causative agent for AIDS and a DNA probe procedure to provide a specific test for malaria. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for product development activities, repayment of asset purchase obligation, repayment of debt, capital equipment and general corporate purposes. |
| # of Units: | 1,000,000 | |||
| Unit Ticker: | - | Unit Price: | $6.00 | |
| Warrant Ticker: | SGENW | Warrant Price: | ||
| Warrant Exercise Date: | Warrant Exercise Price: | |||
| Warrant Expiration Date: | ||||
| Warrant Detachable: | Yes | Warrant Detach Date: | ||
| Warrant Callable: | No |
| Unit Composition: 1 Common Share + 1 Warrant |
| Warrant Entitlement: 1 Common Share |